Zymeworks Inc (ZYME)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Bispecific Antibodiessrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 26/100 (MEDIUM), 28.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 7.77% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
- Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO Hire
- Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
- Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
- Zymeworks Completes Acquisition of Theravance Biopharma
- Zymeworks (ZYME), What Is Behind The Renewed Attention?
- SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
- JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Quality of Outcome Reporting for Older Subgroups in FDA Registration Gastroesophageal Cancer Trials (2010-2024): A Systematic Review. — Cancers (Basel) 2026 Aug 24 PMID 42738270
- Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. — Lancet 2026 Sep 19 PMID 42716074
- Sex, Timing, and Outcomes of Curative-Intent Immunotherapy: A Systematic Review and Meta-Analysis. — JAMA Netw Open 2026 Sep 1 PMID 42709437
- Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. — J Immunother Cancer 2026 Sep 7 PMID 42705861
- Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial. — Int J Gynecol Cancer 2026 Aug 11 PMID 42680635
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Zymeworks Inc.
Full ZYME Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.